Peijia Medical Limited
沛嘉醫療有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR REGISTRATION APPLICATION OF GeminiOne® TRANSCATHETER EDGE-TO-EDGE REPAIR SYSTEM

This announcement is made by Peijia Medical Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company's internally developed GeminiOne® Transcatheter Edge-to-Edge Repair ("**TEER**") System ("**GeminiOne®**") has recently received approval from the National Medical Products Administration of the People's Republic of China (國家藥品監督管理局) (the "**NMPA**") for its registration application.

The approval of GeminiOne® marks the Group's entry into the commercial treatment of mitral regurgitation and represents a significant expansion of its transcatheter valve therapeutic portfolio, following its established presence in the treatment of aortic stenosis and aortic regurgitation.

References are made to the Company's announcements dated February 9, 2026 and April 9, 2026 in relation to the EU MDR CE Mark registration application and the U.S. Early Feasibility Study of GeminiOne®, respectively. The EU MDR CE Mark registration application for GeminiOne® has been submitted, and the U.S. Early Feasibility Study is currently underway.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET GeminiOne® SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi ZHANG
Chairman and Executive Director

Hong Kong, September 11, 2026

As at the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.